0
Upcoming Allied Market Research
2023
Benzodiazepine Drugs Market

Benzodiazepine Drugs Market

by Product (Alprazolam, Clonazepam, Diazepam, Lorazepam), by Application (Anxiety, Insomnia, Alcohol withdrawal, Seizures), by Time of Action (Ultra-short Acting, Short Acting Long Acting) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Report Code: A10255
Nov 2023 | Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Benzodiazepine Drugs Market

Request Now !

Benzodiazepine Drugs Market Outlook - 2027

Benzodiazepines are also called tranquilizers which are used in various medical procedures. Valium and Xanax are the most commonly used benzodiazepine drugs. People often use these drugs without prescriptions and consumer the drugs for their sedating effects, which is considered as an abuse. Having said that, various doctors usually prescribe benzodiazepine drugs for the following legitimate medical conditions such as for anxiety, insomnia, muscle relaxation, alcohol withdrawal, seizure control, inducing amnesia for uncomfortable procedures, and are also prescribed as an anesthetic before a surgery is been performed.

Benzodiazepine Drugs Market

Benzodiazepines directly affect on the central nervous system and cause sedation, muscle relaxation, and also lowers anxiety levels.

There are over 2,000 different benzodiazepines that have been produced to date but only 15 are approved by the FDA in the United States.

Benzodiazepines are differentiated by their effects and how long-duration they last.

1)     Too short-acting- Midazolam, triazolam.

2)     Short-acting - Alprazolam, lorazepam.

3)     Long-acting - Chlordiazepoxide, diazepam

During normal or regular doses, benzodiazepines are used to relieve anxiety and insomnia and they are well tolerated. Occasionally, people take benzodiazepines which make them drowsy or dizzy.                                                           

COVID-19 scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Owing to such factors, COVID 19 is expected to have a significant impact on the Benzodiazepine Drugs market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

Due to the growing frequencies of anxiety, seizures, and growing concerns among people for the preventive measures for stress-related conditions. Additionally, higher prescriptions for benzodiazepine drugs are increasing in rate due to the adoption of generic drugs that are moving the global benzodiazepine drugs market.

 On the other hand, increasing benzodiazepine drug abuse and several reported cases of overdoses which lead to the death of the consumer. As there has been a growth in the popularity of generic drugs, it has resulted in an inactive growth of the market. Also, the capital requirements are very high for the development of quality branded drugs.

Consumption of benzodiazepine drugs for a very long time can lead to various issues like breathing problems, weakness, dizziness, tremors, brain damage, pneumonia, or even death.

New product launches and acquisitions to flourish the market:

On May 26th, 2020, Arvelle Therapeutics announced that they have closed the final tranche of its Series A financing round for Benzodiazepine drugs. The final tranche was activated by the European Medicines Agency’s (EMA) and they have recently accepted the marketing authorization application (MAA).

On May 12th, 2020, Hikma Pharmaceuticals, announced Propofol Injectable Emulsion, USP, 20 ml, 50 ml and 100 ml Vials, in the US which is followed by the approval of Abbreviated New Drug Application by the U.S. Food and Drug Administration.

Surge in usage in hospital applications:

There are a large number of hospitals and retail pharmacies and they are continuing to grow further which is makes it easy for individuals to purchase benzodiazepine drugs. The retail pharmacies are the highest consumers of the benzodiazepine drug market. Other consumers like online pharmacies and mail pharmacies, are highly profitable due to the better discount rates on online platforms and popularity owing to convenience.

Key benefits of the report:

  • This study presents the analytical depiction of the global Benzodiazepine Drugs industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Benzodiazepine Drugs market share.
  • The current market is quantitatively analyzed to highlight the global Benzodiazepine Drugs market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global Benzodiazepine Drugs market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Benzodiazepine Drugs Market research report:

  • What are the leading market players active in the Benzodiazepine Drugs market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

Benzodiazepine Drugs Market Report Highlights

Aspects Details
By Product
  • Alprazolam
  • Clonazepam
  • Diazepam
  • Lorazepam
By Application
  • Anxiety
  • Insomnia
  • Alcohol withdrawal
  • Seizures
By Time of Action
  • Ultra-short Acting
  • Short Acting Long Acting
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players H.Lundbeck A/S., F.Hoffmann-La Roche Ltd., Sun Pharmaceuticals Industries Ltd, Apotex Inc., Pfizer Inc., Mylan, N.V, Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Bausch Health Companies, Inc., Amneal Pharmaceuticals LLC
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: BENZODIAZEPINE DRUGS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Alprazolam

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Clonazepam

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Diazepam

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Lorazepam

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: BENZODIAZEPINE DRUGS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Anxiety

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Insomnia

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Alcohol Withdrawal

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Seizures

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: BENZODIAZEPINE DRUGS MARKET, BY TIME OF ACTION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Time Of Action

    • 6.2. Ultra-short Acting

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Short Acting Long Acting

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

  • CHAPTER 7: BENZODIAZEPINE DRUGS MARKET, BY DISTRIBUTION CHANNEL

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Distribution Channel

    • 7.2. Hospital Pharmacies

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Retail Pharmacies

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

  • CHAPTER 8: BENZODIAZEPINE DRUGS MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product

      • 8.2.3. Market Size and Forecast, By Application

      • 8.2.4. Market Size and Forecast, By Time Of Action

      • 8.2.5. Market Size and Forecast, By Distribution Channel

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Benzodiazepine Drugs Market

        • 8.2.7.1. Market Size and Forecast, By Product
        • 8.2.7.2. Market Size and Forecast, By Application
        • 8.2.7.3. Market Size and Forecast, By Time Of Action
        • 8.2.7.4. Market Size and Forecast, By Distribution Channel
      • 8.2.8. Canada Benzodiazepine Drugs Market

        • 8.2.8.1. Market Size and Forecast, By Product
        • 8.2.8.2. Market Size and Forecast, By Application
        • 8.2.8.3. Market Size and Forecast, By Time Of Action
        • 8.2.8.4. Market Size and Forecast, By Distribution Channel
      • 8.2.9. Mexico Benzodiazepine Drugs Market

        • 8.2.9.1. Market Size and Forecast, By Product
        • 8.2.9.2. Market Size and Forecast, By Application
        • 8.2.9.3. Market Size and Forecast, By Time Of Action
        • 8.2.9.4. Market Size and Forecast, By Distribution Channel
    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product

      • 8.3.3. Market Size and Forecast, By Application

      • 8.3.4. Market Size and Forecast, By Time Of Action

      • 8.3.5. Market Size and Forecast, By Distribution Channel

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Benzodiazepine Drugs Market

        • 8.3.7.1. Market Size and Forecast, By Product
        • 8.3.7.2. Market Size and Forecast, By Application
        • 8.3.7.3. Market Size and Forecast, By Time Of Action
        • 8.3.7.4. Market Size and Forecast, By Distribution Channel
      • 8.3.8. Germany Benzodiazepine Drugs Market

        • 8.3.8.1. Market Size and Forecast, By Product
        • 8.3.8.2. Market Size and Forecast, By Application
        • 8.3.8.3. Market Size and Forecast, By Time Of Action
        • 8.3.8.4. Market Size and Forecast, By Distribution Channel
      • 8.3.9. Italy Benzodiazepine Drugs Market

        • 8.3.9.1. Market Size and Forecast, By Product
        • 8.3.9.2. Market Size and Forecast, By Application
        • 8.3.9.3. Market Size and Forecast, By Time Of Action
        • 8.3.9.4. Market Size and Forecast, By Distribution Channel
      • 8.3.10. Spain Benzodiazepine Drugs Market

        • 8.3.10.1. Market Size and Forecast, By Product
        • 8.3.10.2. Market Size and Forecast, By Application
        • 8.3.10.3. Market Size and Forecast, By Time Of Action
        • 8.3.10.4. Market Size and Forecast, By Distribution Channel
      • 8.3.11. UK Benzodiazepine Drugs Market

        • 8.3.11.1. Market Size and Forecast, By Product
        • 8.3.11.2. Market Size and Forecast, By Application
        • 8.3.11.3. Market Size and Forecast, By Time Of Action
        • 8.3.11.4. Market Size and Forecast, By Distribution Channel
      • 8.3.12. Russia Benzodiazepine Drugs Market

        • 8.3.12.1. Market Size and Forecast, By Product
        • 8.3.12.2. Market Size and Forecast, By Application
        • 8.3.12.3. Market Size and Forecast, By Time Of Action
        • 8.3.12.4. Market Size and Forecast, By Distribution Channel
      • 8.3.13. Rest Of Europe Benzodiazepine Drugs Market

        • 8.3.13.1. Market Size and Forecast, By Product
        • 8.3.13.2. Market Size and Forecast, By Application
        • 8.3.13.3. Market Size and Forecast, By Time Of Action
        • 8.3.13.4. Market Size and Forecast, By Distribution Channel
    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product

      • 8.4.3. Market Size and Forecast, By Application

      • 8.4.4. Market Size and Forecast, By Time Of Action

      • 8.4.5. Market Size and Forecast, By Distribution Channel

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Benzodiazepine Drugs Market

        • 8.4.7.1. Market Size and Forecast, By Product
        • 8.4.7.2. Market Size and Forecast, By Application
        • 8.4.7.3. Market Size and Forecast, By Time Of Action
        • 8.4.7.4. Market Size and Forecast, By Distribution Channel
      • 8.4.8. Japan Benzodiazepine Drugs Market

        • 8.4.8.1. Market Size and Forecast, By Product
        • 8.4.8.2. Market Size and Forecast, By Application
        • 8.4.8.3. Market Size and Forecast, By Time Of Action
        • 8.4.8.4. Market Size and Forecast, By Distribution Channel
      • 8.4.9. India Benzodiazepine Drugs Market

        • 8.4.9.1. Market Size and Forecast, By Product
        • 8.4.9.2. Market Size and Forecast, By Application
        • 8.4.9.3. Market Size and Forecast, By Time Of Action
        • 8.4.9.4. Market Size and Forecast, By Distribution Channel
      • 8.4.10. South Korea Benzodiazepine Drugs Market

        • 8.4.10.1. Market Size and Forecast, By Product
        • 8.4.10.2. Market Size and Forecast, By Application
        • 8.4.10.3. Market Size and Forecast, By Time Of Action
        • 8.4.10.4. Market Size and Forecast, By Distribution Channel
      • 8.4.11. Australia Benzodiazepine Drugs Market

        • 8.4.11.1. Market Size and Forecast, By Product
        • 8.4.11.2. Market Size and Forecast, By Application
        • 8.4.11.3. Market Size and Forecast, By Time Of Action
        • 8.4.11.4. Market Size and Forecast, By Distribution Channel
      • 8.4.12. Thailand Benzodiazepine Drugs Market

        • 8.4.12.1. Market Size and Forecast, By Product
        • 8.4.12.2. Market Size and Forecast, By Application
        • 8.4.12.3. Market Size and Forecast, By Time Of Action
        • 8.4.12.4. Market Size and Forecast, By Distribution Channel
      • 8.4.13. Malaysia Benzodiazepine Drugs Market

        • 8.4.13.1. Market Size and Forecast, By Product
        • 8.4.13.2. Market Size and Forecast, By Application
        • 8.4.13.3. Market Size and Forecast, By Time Of Action
        • 8.4.13.4. Market Size and Forecast, By Distribution Channel
      • 8.4.14. Indonesia Benzodiazepine Drugs Market

        • 8.4.14.1. Market Size and Forecast, By Product
        • 8.4.14.2. Market Size and Forecast, By Application
        • 8.4.14.3. Market Size and Forecast, By Time Of Action
        • 8.4.14.4. Market Size and Forecast, By Distribution Channel
      • 8.4.15. Rest of Asia Pacific Benzodiazepine Drugs Market

        • 8.4.15.1. Market Size and Forecast, By Product
        • 8.4.15.2. Market Size and Forecast, By Application
        • 8.4.15.3. Market Size and Forecast, By Time Of Action
        • 8.4.15.4. Market Size and Forecast, By Distribution Channel
    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product

      • 8.5.3. Market Size and Forecast, By Application

      • 8.5.4. Market Size and Forecast, By Time Of Action

      • 8.5.5. Market Size and Forecast, By Distribution Channel

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Benzodiazepine Drugs Market

        • 8.5.7.1. Market Size and Forecast, By Product
        • 8.5.7.2. Market Size and Forecast, By Application
        • 8.5.7.3. Market Size and Forecast, By Time Of Action
        • 8.5.7.4. Market Size and Forecast, By Distribution Channel
      • 8.5.8. South Africa Benzodiazepine Drugs Market

        • 8.5.8.1. Market Size and Forecast, By Product
        • 8.5.8.2. Market Size and Forecast, By Application
        • 8.5.8.3. Market Size and Forecast, By Time Of Action
        • 8.5.8.4. Market Size and Forecast, By Distribution Channel
      • 8.5.9. Saudi Arabia Benzodiazepine Drugs Market

        • 8.5.9.1. Market Size and Forecast, By Product
        • 8.5.9.2. Market Size and Forecast, By Application
        • 8.5.9.3. Market Size and Forecast, By Time Of Action
        • 8.5.9.4. Market Size and Forecast, By Distribution Channel
      • 8.5.10. UAE Benzodiazepine Drugs Market

        • 8.5.10.1. Market Size and Forecast, By Product
        • 8.5.10.2. Market Size and Forecast, By Application
        • 8.5.10.3. Market Size and Forecast, By Time Of Action
        • 8.5.10.4. Market Size and Forecast, By Distribution Channel
      • 8.5.11. Argentina Benzodiazepine Drugs Market

        • 8.5.11.1. Market Size and Forecast, By Product
        • 8.5.11.2. Market Size and Forecast, By Application
        • 8.5.11.3. Market Size and Forecast, By Time Of Action
        • 8.5.11.4. Market Size and Forecast, By Distribution Channel
      • 8.5.12. Rest of LAMEA Benzodiazepine Drugs Market

        • 8.5.12.1. Market Size and Forecast, By Product
        • 8.5.12.2. Market Size and Forecast, By Application
        • 8.5.12.3. Market Size and Forecast, By Time Of Action
        • 8.5.12.4. Market Size and Forecast, By Distribution Channel
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Pfizer Inc.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. F.Hoffmann-La Roche Ltd.

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Amneal Pharmaceuticals LLC

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Bausch Health Companies, Inc.

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Apotex Inc.

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Sun Pharmaceuticals Industries Ltd

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Mylan, N.V

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Teva Pharmaceutical Industries Ltd

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Aurobindo Pharma

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. H.Lundbeck A/S.

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL BENZODIAZEPINE DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR ALPRAZOLAM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR CLONAZEPAM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR DIAZEPAM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR LORAZEPAM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL BENZODIAZEPINE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR ANXIETY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR INSOMNIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR ALCOHOL WITHDRAWAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR SEIZURES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL BENZODIAZEPINE DRUGS MARKET, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR ULTRA-SHORT ACTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR SHORT ACTING LONG ACTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL BENZODIAZEPINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL BENZODIAZEPINE DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL BENZODIAZEPINE DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA BENZODIAZEPINE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. U.S. BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 24. U.S. BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. U.S. BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 26. U.S. BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. CANADA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 28. CANADA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. CANADA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 30. CANADA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE BENZODIAZEPINE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ITALY BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 49. ITALY BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. ITALY BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 51. ITALY BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. UK BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 57. UK BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. UK BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 59. UK BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. RUSSIA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 61. RUSSIA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. RUSSIA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 63. RUSSIA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. REST OF EUROPE BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 67. REST OF EUROPE BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC BENZODIAZEPINE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. ASIA-PACIFIC BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. CHINA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 74. CHINA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 75. CHINA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 76. CHINA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. JAPAN BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 78. JAPAN BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 79. JAPAN BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 80. JAPAN BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. INDIA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 82. INDIA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. INDIA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 84. INDIA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH KOREA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. AUSTRALIA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 90. AUSTRALIA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 91. AUSTRALIA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 92. AUSTRALIA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 93. THAILAND BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 94. THAILAND BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 95. THAILAND BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 96. THAILAND BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 97. MALAYSIA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 98. MALAYSIA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 99. MALAYSIA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 100. MALAYSIA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 101. INDONESIA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 102. INDONESIA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 103. INDONESIA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 104. INDONESIA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 105. REST OF ASIA PACIFIC BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 106. REST OF ASIA PACIFIC BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 107. REST OF ASIA PACIFIC BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 108. REST OF ASIA PACIFIC BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 109. LAMEA BENZODIAZEPINE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 110. LAMEA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 111. LAMEA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 112. LAMEA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 113. LAMEA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 114. BRAZIL BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 115. BRAZIL BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 116. BRAZIL BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 117. BRAZIL BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 118. SOUTH AFRICA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 119. SOUTH AFRICA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 120. SOUTH AFRICA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 121. SOUTH AFRICA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 122. SAUDI ARABIA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 123. SAUDI ARABIA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 124. SAUDI ARABIA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 125. SAUDI ARABIA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 126. UAE BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 127. UAE BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 128. UAE BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 129. UAE BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 130. ARGENTINA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 131. ARGENTINA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 132. ARGENTINA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 133. ARGENTINA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 134. REST OF LAMEA BENZODIAZEPINE DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 135. REST OF LAMEA BENZODIAZEPINE DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 136. REST OF LAMEA BENZODIAZEPINE DRUGS, BY TIME OF ACTION, 2022-2032 ($MILLION)
  • TABLE 137. REST OF LAMEA BENZODIAZEPINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 138. PFIZER INC.: KEY EXECUTIVES
  • TABLE 139. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 140. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 141. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 142. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. F.HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 144. F.HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 145. F.HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 146. F.HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 147. F.HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 149. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 150. AMNEAL PHARMACEUTICALS LLC: OPERATING SEGMENTS
  • TABLE 151. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 152. AMNEAL PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. BAUSCH HEALTH COMPANIES, INC.: KEY EXECUTIVES
  • TABLE 154. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT
  • TABLE 155. BAUSCH HEALTH COMPANIES, INC.: OPERATING SEGMENTS
  • TABLE 156. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO
  • TABLE 157. BAUSCH HEALTH COMPANIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 158. APOTEX INC.: KEY EXECUTIVES
  • TABLE 159. APOTEX INC.: COMPANY SNAPSHOT
  • TABLE 160. APOTEX INC.: OPERATING SEGMENTS
  • TABLE 161. APOTEX INC.: PRODUCT PORTFOLIO
  • TABLE 162. APOTEX INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 163. SUN PHARMACEUTICALS INDUSTRIES LTD: KEY EXECUTIVES
  • TABLE 164. SUN PHARMACEUTICALS INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 165. SUN PHARMACEUTICALS INDUSTRIES LTD: OPERATING SEGMENTS
  • TABLE 166. SUN PHARMACEUTICALS INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 167. SUN PHARMACEUTICALS INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 168. MYLAN, N.V: KEY EXECUTIVES
  • TABLE 169. MYLAN, N.V: COMPANY SNAPSHOT
  • TABLE 170. MYLAN, N.V: OPERATING SEGMENTS
  • TABLE 171. MYLAN, N.V: PRODUCT PORTFOLIO
  • TABLE 172. MYLAN, N.V: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 173. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
  • TABLE 174. TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 175. TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
  • TABLE 176. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 177. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 178. AUROBINDO PHARMA: KEY EXECUTIVES
  • TABLE 179. AUROBINDO PHARMA: COMPANY SNAPSHOT
  • TABLE 180. AUROBINDO PHARMA: OPERATING SEGMENTS
  • TABLE 181. AUROBINDO PHARMA: PRODUCT PORTFOLIO
  • TABLE 182. AUROBINDO PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 183. H.LUNDBECK A/S.: KEY EXECUTIVES
  • TABLE 184. H.LUNDBECK A/S.: COMPANY SNAPSHOT
  • TABLE 185. H.LUNDBECK A/S.: OPERATING SEGMENTS
  • TABLE 186. H.LUNDBECK A/S.: PRODUCT PORTFOLIO
  • TABLE 187. H.LUNDBECK A/S.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL BENZODIAZEPINE DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL BENZODIAZEPINE DRUGS MARKET
  • FIGURE 3. SEGMENTATION BENZODIAZEPINE DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN BENZODIAZEPINE DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALBENZODIAZEPINE DRUGS MARKET
  • FIGURE 11. BENZODIAZEPINE DRUGS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. BENZODIAZEPINE DRUGS MARKET FOR ALPRAZOLAM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. BENZODIAZEPINE DRUGS MARKET FOR CLONAZEPAM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. BENZODIAZEPINE DRUGS MARKET FOR DIAZEPAM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. BENZODIAZEPINE DRUGS MARKET FOR LORAZEPAM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. BENZODIAZEPINE DRUGS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 17. BENZODIAZEPINE DRUGS MARKET FOR ANXIETY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. BENZODIAZEPINE DRUGS MARKET FOR INSOMNIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. BENZODIAZEPINE DRUGS MARKET FOR ALCOHOL WITHDRAWAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. BENZODIAZEPINE DRUGS MARKET FOR SEIZURES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. BENZODIAZEPINE DRUGS MARKET SEGMENTATION, BY BY TIME OF ACTION
  • FIGURE 22. BENZODIAZEPINE DRUGS MARKET FOR ULTRA-SHORT ACTING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. BENZODIAZEPINE DRUGS MARKET FOR SHORT ACTING LONG ACTING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. BENZODIAZEPINE DRUGS MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 25. BENZODIAZEPINE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. BENZODIAZEPINE DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 28. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 29. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 30. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 31. COMPETITIVE DASHBOARD
  • FIGURE 32. COMPETITIVE HEATMAP: BENZODIAZEPINE DRUGS MARKET
  • FIGURE 33. Top player positioning, 2022
  • FIGURE 34. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. F.HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. F.HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. F.HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. AMNEAL PHARMACEUTICALS LLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. BAUSCH HEALTH COMPANIES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. APOTEX INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. APOTEX INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. APOTEX INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. SUN PHARMACEUTICALS INDUSTRIES LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. SUN PHARMACEUTICALS INDUSTRIES LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. SUN PHARMACEUTICALS INDUSTRIES LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. MYLAN, N.V: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. MYLAN, N.V: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. MYLAN, N.V: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. AUROBINDO PHARMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. AUROBINDO PHARMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. AUROBINDO PHARMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. H.LUNDBECK A/S.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. H.LUNDBECK A/S.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. H.LUNDBECK A/S.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Benzodiazepine Drugs Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers